相关实验视频

Updated: Jan 8, 2026

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

在现场重编程衰老的微环境通过增强内源的衰老作用的先进的动脉样硬化管理

Zhiyue Wang¹, Xing Chen², Yutong Xu^3,4

¹Department of Radiology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu 210008, China.

|December 23, 2025

概括

这项研究介绍了L-pKNZ,这是一种新型纳米药物,通过激活自和细胞,清除衰老的泡细胞,从而使血管复苏并改善动脉样硬化.

科学领域:

生物医学工程生物医学工程
心血管研究研究心血管研究
纳米医学是一种纳米医学.

背景情况:

晚期动脉样硬化 (AS) 呈现出显著的心血管疾病风险,尽管降脂疗法.
衰老的泡细胞 (FCs) 通过细胞交叉声调在先进的斑块中产生病态的微环境.
现有的老化剂主要诱导亡,限制了它们的治疗范围.

研究的目的:

开发一种新型纳米药物 (L-pKNZ),针对AS中的衰老FC.
调查L-pKNZ的作用机制,重点关注自和血细胞分裂.
建立一个用于成像和处理AS老化的微环境的theranostic平台.

主要方法:

合成一种以热利性伊米达酸框架-8 (ZIF-8) 为基础的纳米医学,L-pKNZ.
在体外和体内实验中评估L-pKNZ对FC和血管细胞的影响.
多组学分析,以了解分子机制.
用68Ga对L-pKNZ进行放射性标记,用于微PET/CT成像.

主要成果:

与传统的老化药物不同,L-pKNZ激活了FC自,并增强了巨细胞效能.
这种内生老化系统有效地减轻了FC的过载,并重新编程了老化的微环境.
实验证实了血管再生和AS改善.
标有Ga的L-pKNZ能够对老化的微环境进行非侵入性成像.

结论:

通过向衰老的FCs,L-pKNZ代表了AS的新治疗策略.
开发的纳米医药通过内源老化系统促进血管健康.
这项研究为与年龄相关的疾病提供了一种多功能的精神治疗平台,具有超越AS的潜在应用.

关键词:

在PET/CT成像中使用PET/CT成像这是一种ZIF-8纳米粒子.晚期动脉样硬化症的发生自自是自的过程.这种细胞的形成是Efferocytosis.衰老是一种老化.

更多相关视频

Evaluation of Injury-induced Senescence and In Vivo Reprogramming in the Skeletal Muscle

Evaluation of Injury-induced Senescence and In Vivo Reprogramming in the Skeletal Muscle

Published on: October 26, 2017

Techniques to Induce and Quantify Cellular Senescence

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis IV: Nursing Management

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...